The Prognostic Value of the Human Kallikrein Gene 9 (KLK9) in Breast Cancer
| العنوان: | The Prognostic Value of the Human Kallikrein Gene 9 (KLK9) in Breast Cancer |
|---|---|
| المؤلفون: | Terukazu Nakamura, Piero Sismondi, Eleftherios P. Diamandis, Nicoletta Biglia, Andreas Scorilas, George M. Yousef, R. Roagna, Riccardo Ponzone, Mohamed Abd Ellatif, Furio Maggiorotto |
| المصدر: | Breast Cancer Research and Treatment. 78:149-158 |
| بيانات النشر: | Springer Science and Business Media LLC, 2003. |
| سنة النشر: | 2003 |
| مصطلحات موضوعية: | Adult, serine proteases, Cancer Research, Prognostic variable, Mammary gland, Gene Expression, Estrogen receptor, Breast Neoplasms, Biology, KLK9, PSA, breast cancer, Breast cancer, Predictive Value of Tests, Progesterone receptor, Biomarkers, Tumor, medicine, Humans, cancer genes, cancer predictive markers, kallikreins, prognostic markers, tumor markers, Mastectomy, Survival analysis, Aged, Aged, 80 and over, Reverse Transcriptase Polymerase Chain Reaction, Carcinoma, Ductal, Breast, Hazard ratio, Kallikrein, Middle Aged, Prognosis, medicine.disease, Combined Modality Therapy, Survival Analysis, Neoplasm Proteins, Carcinoma, Lobular, medicine.anatomical_structure, Oncology, Cancer research, Female, Kallikreins |
| الوصف: | Summary Background. Many members of the human kallikrein gene family were found to be differentially expressed in various malignancies and some of them are useful diagnostic/prognostic markers. KLK9 is a newly discovered human kallikrein gene that is expressed in several tissues including thymus, spinal cord, testis, prostate, breast, and ovary. Like other kallikreins, the KLK9 gene was found to be regulated by steroid hormones, mainly estrogens and progestins, in cancer cell lines. Experimental design. We studied the expression of KLK9 by quantitative RT-PCR in 169 breast cancer patients of different stages, grades and histological types. We also compared the relation between KLK9 expression and other clinicopathological variables and patient survival. Results. KLK9 expression is significantly higher in patients with early stage cancers (p = 0.039) and in patients with small tumor size (< 2c m) (p = 0.028). Kaplan-Meier survival curves demonstrated that KLK9-positive patients have longer disease-free and overall survival (p = 0.015 and 0.036, respectively). Univariate and multivariate analysis also indicates that KLK9 expression is associated with increased disease-free and overall survival. When the Cox proportional hazard regression analysis was applied to subgroups of patients, KLK9 expression was found to be a significant predictor of disease-free survival in the estrogen receptor (ER) and progesterone receptor (PR) negative subgroups of patients (Hazard Ratio ‘HR’ = 0.28, and 0.38, respectively, and p = 0.011 and 0.028, respectively). After adjusting for other known prognostic variables, KLK9 retained its independent prognostic value in these subgroups of patients. Similar results were obtained for overall survival. Conclusions. KLK9 is a new potential independent marker of favorable prognosis in breast cancer. |
| تدمد: | 1573-7217 0167-6806 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66bcd5d4f6a777bcaff1bc8663661381Test https://doi.org/10.1023/a:1022931403825Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....66bcd5d4f6a777bcaff1bc8663661381 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15737217 01676806 |
|---|